Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL
GLOBETECH PUBLISHING LLC

Novel Nanosponge Vaccine Protects Mice from MRSA Toxin

By BiotechDaily International staff writers
Posted on 10 Dec 2013
Image: The glowing yellow specks in the image show uptake of the nanosponge vaccine by a mouse immune system dendritic cell. The detained alpha-hemolysin toxins were labeled with a fluorescent dye, which glows yellow. The cell membrane was stained red and the nuclei stained blue (Photo courtesy of the University of California, San Diego,  Department of NanoEngineering).
Image: The glowing yellow specks in the image show uptake of the nanosponge vaccine by a mouse immune system dendritic cell. The detained alpha-hemolysin toxins were labeled with a fluorescent dye, which glows yellow. The cell membrane was stained red and the nuclei stained blue (Photo courtesy of the University of California, San Diego, Department of NanoEngineering).
Image: The nanosponges at the foundation of the experimental “toxoid vaccine” platform are biocompatible particles made of a polymer core (light-blue-green color) wrapped in a red-blood-cell membrane (orange). Each nanosponge's red-blood-cell membrane seizes and detains the Staphylococcus aureus alpha-hemolysin toxin (blue) without compromising the toxin’s structural integrity through heating or chemical processing. These toxin-studded nanosponges served as vaccines capable of triggering neutralizing antibodies and fighting off otherwise lethal doses of the toxin in mice (Photo courtesy of the University of California, San Diego,  Department of NanoEngineering).
Image: The nanosponges at the foundation of the experimental “toxoid vaccine” platform are biocompatible particles made of a polymer core (light-blue-green color) wrapped in a red-blood-cell membrane (orange). Each nanosponge's red-blood-cell membrane seizes and detains the Staphylococcus aureus alpha-hemolysin toxin (blue) without compromising the toxin’s structural integrity through heating or chemical processing. These toxin-studded nanosponges served as vaccines capable of triggering neutralizing antibodies and fighting off otherwise lethal doses of the toxin in mice (Photo courtesy of the University of California, San Diego, Department of NanoEngineering).
A novel vaccine based on "nanosponges" that sequester toxic, pore-forming toxoids—such as that produced by MRSA (methicylin resistant Staphylococcus aureus)—permits presentation of these toxins to immune system defensive cells without danger of damaging them.

It is not possible to deliver a native pore-forming toxin to immune cells without damaging the cells. However, the heating or chemical processing required to neutralize the toxin can compromise the toxin's structural integrity and reduce the value of the vaccine.

To get around this problem, investigators at the University of California, San Diego (USA) developed "nanosponges.” These are biocompatible particles made of a polymer core wrapped in a red blood cell membrane. The red blood cell coating allows the nanosponge to incorporate and hold I alpha-hemolysin toxin without compromising the toxin’s structural integrity through heating or chemical processing. Despite being intact structurally, the trapped toxoid is rendered incapable of damaging other cells.

A paper published in the December 1, 2013, online edition of the journal Nature Nanotechnology presented results from experiments in which nanosponges loaded with toxoid were used to protect mice from MRSA infection. After one injection of the vaccine, 50% of the nanosponge-treated animals survived as compared to fewer than 10% of mice that had been vaccinated with heat-inactivated toxoid. An additional two booster shots increased the survival rate for the nanosponge-vaccinated animals to 100% compared to 90% for those vaccinated with the heat-treated toxin.

"The more you heat it, the safer the toxin is, but the more you heat it, the more you damage the structure of the protein," said senior author Dr. Liangfang Zhang, professor of nanoengineering at the University of California, San Diego. "And this structure is what the immune cell recognizes, and builds its antibodies against. Before this there was no way you could deliver a native toxin to the immune cells without damaging the cells, but this technology allows us to do this."

"The nanosponge vaccine was also able to completely prevent the toxin's damages in the skin, where MRSA infections frequently take place," said Dr. Zhang. "The particles work so beautifully that it might be possible to detain several toxins at once on them, creating one vaccine against many types of pore-forming toxins, from Staphylococcus to snake venom."

Related Links:

University of California, San Diego



Channels

Genomics/Proteomics

view channel
Image: Researchers have generated disease-free stem cells from patients with mitochondrial disease that can be converted into any cell type including neuronal progenitors (left) or heart cells (right). These could potentially be used for future transplantation into patients (Photo courtesy of Salk Institute of Biological Studies).

Methods Developed to Generate Normal Stem Cells from Patients with Mitochondrial Defects

A recent paper described two methods for converting cells from patients with mitochondrial defects into normal pluripotent stem cells that could be induced to differentiate into several different types of tissues.... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.